Scarica l'app Stockscreener
2.38
0.85%
0.02
Dopo l'orario di chiusura:
2.30
-0.08
-3.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$2.36
Aprire:
$2.4
Volume 24 ore:
143.22K
Relative Volume:
1.03
Capitalizzazione di mercato:
$6.58M
Reddito:
-
Utile/perdita netta:
$-26.92M
Rapporto P/E:
-4.6667
EPS:
-0.51
Flusso di cassa netto:
$-18.92M
1 W Prestazione:
+13.33%
1M Prestazione:
-67.78%
6M Prestazione:
-84.13%
1 anno Prestazione:
-93.80%
Intervallo 1D:
$2.25
$2.40
Intervallo di 1 settimana:
$1.98
$2.78
Portata 52W:
$1.98
$66.60
Cel-Sci Corp. Stock (CVM) Company Profile
Nome
Cel-Sci Corp.
Settore
Industria
Telefono
703-506-9460
Indirizzo
8229 Boone Boulevard, Suite 802, Vienna, VA
Confronta CVM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
2.38 | 6.58M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-01-13 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-02 | Iniziato | Dawson James | Buy |
Cel-Sci Corp. Borsa (CVM) Ultime notizie
CVM stock touches 52-week low at $2.32 amid sharp annual decline By Investing.com - Investing.com South Africa
CVM stock touches 52-week low at $2.32 amid sharp annual decline - Investing.com Australia
CEL-SCI Closes $5 Million Public Offering - marketscreener.com
Cancer Immunotherapy Firm CEL-SCI Secures $5M Funding to Advance Multikine Treatment - Stock Titan
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Dow Moves Higher; US Initial Jobless Claims Fall - Benzinga
CEL-SCI (CVM) Prices Public Offering Amid Stock Slump - GuruFocus
CEL-SCI Prices Offering of 2 Million Shares - marketscreener.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Applicati - GuruFocus
CVM Stock Offering Priced Below Previous Closing Value | CVM Sto - GuruFocus
Cel-Sci Says Prices Public Offering Of 2 Million Shares At $2.50 Per Share - marketscreener.com
CEL-SCI Raises $5M in New Stock Offering: Cancer Immunotherapy Program Multikine Gets Fresh Funding - Stock Titan
CVM stock touches 52-week low at $4.67 amid sharp annual decline By Investing.com - Investing.com South Africa
CEL-SCI Announces Planned Public Offering; Shares Fall After Hours - marketscreener.com
CEL-SCI announces public stock offering to fund cancer therapy By Investing.com - Investing.com Canada
CEL-SCI Corporation (CVM) Plans Public Offering for R&D and Corporate Needs | CVM Stock News - GuruFocus
CEL-SCI announces public stock offering to fund cancer therapy - Investing.com
CEL-SCI Announces Strategic Public Offering: Cancer Immunotherapy Development Gets Major Funding Push - Stock Titan
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - BioSpace
CVM stock touches 52-week low at $4.67 amid sharp annual decline - Investing.com Canada
CEL-SCI Completes Saudi Breakthrough Medicine Designation Application for Multikine Cancer Drug - marketscreener.com
CEL-SCI seeks SFDA nod for cancer drug Multikine By Investing.com - Investing.com Canada
CEL-SCI seeks SFDA nod for cancer drug Multikine - Investing.com
CEL-SCI (CVM) Prepares to Submit Breakthrough Medicine Application in Saudi Arabia | CVM Stock News - GuruFocus
Revolutionary Cancer Drug Shows 73% Survival Rate, Nears Fast-Track Approval in Saudi Arabia - Stock Titan
CEL-SCI Implements 1-for-30 Stock Split To Support Share Price - Nasdaq
CEL-SCI approves 1-for-30 stock combination By Investing.com - Investing.com South Africa
CEL-SCI (CVM) Approves 1-for-30 Stock Consolidation | CVM Stock News - GuruFocus
CEL-SCI approves 1-for-30 stock combination - Investing.com Australia
CEL-SCI's Board Approves 1-for-30 Share Combination - marketscreener.com
CEL-SCI Announces Combination of Common Stock | CVM Stock News - GuruFocus
CEL-SCI expects 1 for 30 combination of common stock to be implemented on May 20 - TipRanks
CEL-SCI Plans Major 1:30 Reverse Split as CEO Hints at Upcoming Catalysts - Stock Titan
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Defense World
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results | C - GuruFocus
CEL-SCI Cancer Drug Shows 95% Quality of Life Success in Phase 3 Trial | CVM Stock News - Stock Titan
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Business Wire
Cel-Sci: Fiscal Q2 Earnings Snapshot - New Haven Register
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
CEL-SCI Co. (NYSE:CVM) Shares Sold by Geode Capital Management LLC - Defense World
LD Micro 360 Companies --Set to Present this Week. - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Take off with Cel-Sci Corp (CVM): Get ready for trading - Sete News
Top investors say Ares Management Corp (ARES) ticks everything they need - Sete News
A stock that deserves closer examination: Cel-Sci Corp (CVM) - uspostnews.com
Investing in Cel-Sci Corp (CVM) Is Getting More Attractive - knoxdaily.com
CVM’s Stock Journey: What Investors Need to Know About Cel-Sci Corp’s Performance - investchronicle.com
Curbline Properties Corp (CURB) Becoming More Attractive for Investors - knoxdaily.com
Metric Analysis: Coca-Cola Femsa S.A.B. DE C.V. ADR (KOF)’s Key Ratios in the Limelight - DWinneX
Analyzing Ratios: Cel-Sci Corp (CVM)’s Financial Story Unveiled - DWinneX
Ratios Revealed: Decoding Applied Dna Sciences Inc (APDN)’s Financial Health - DWinneX
Cel-Sci Corp. Azioni (CVM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):